Title :

Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort.

Author(s) :

Carvajal Alegria, Guillermo [Auteur]
CHRU Brest - Service de Rhumatologie [CHU - BREST - Rhumato]
Guellec, Dewi [Auteur]
CHRU Brest - Service de Rhumatologie [CHU - BREST - Rhumato]
Mariette, Xavier [Auteur]
Service de rhumatologie
Gottenberg, Jacques-Eric [Auteur]
Immuno-Rhumatologie Moléculaire [IRM]
Dernis, Emmanuelle [Auteur]
Service de Rhumatologie [CH Le Mans]
Dubost, Jean-Jacques [Auteur]
Service Rhumatologie [CHU Clermont-Ferrand]
Trouvin, Anne-Priscille [Auteur]
Université de Rouen Normandie [UNIROUEN]
Hachulla, Eric [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Larroche, Claire [Auteur]
Hôpital Avicenne [AP-HP]
Le Guern, Veronique [Auteur]
CHU Saint-Antoine [AP-HP]
Cornec, Divi [Auteur]
CHRU Brest - Service de Rhumatologie [CHU - BREST - Rhumato]
Devauchelle-Pensec, Valerie [Auteur]
CHRU Brest - Service de Rhumatologie [CHU - BREST - Rhumato]
Saraux, Alain [Auteur]
CHRU Brest - Service de Rhumatologie [CHU - BREST - Rhumato]

Journal title :

RMD Open : Rheumatic & Musculoskeletal Diseases

Abbreviated title :

RMD Open

Volume number :

2

Pages :

e000179

Publication date :

2016-01-01

ISSN :

2056-5933

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVES: Neurological manifestations seem common in primary Sjogren's syndrome (pSS) but their reported prevalences vary. We investigated the prevalence and epidemiology of neurological manifestations in a French ...
Show more >OBJECTIVES: Neurological manifestations seem common in primary Sjogren's syndrome (pSS) but their reported prevalences vary. We investigated the prevalence and epidemiology of neurological manifestations in a French nationwide multicentre prospective cohort of patients with pSS, the Assessment of Systemic Signs and Evolution in Sjogren's syndrome (ASSESS) cohort. METHODS: The ASSESS cohort, established in 2006, includes 395 patients fulfilling American-European Consensus Group criteria for pSS. Demographic and clinical data were compared between patient groups with and without neurological manifestations, and across patient groups with peripheral nervous system (PNS) manifestations, central nervous system (CNS) manifestations and no neurological manifestations. RESULTS: Data at inclusion were available for 392 patients, whose mean age was 58+/-12 years. Mean follow-up was 33.9 months. Neurological manifestations were present in 74/392 (18.9%) patients, including 63 (16%) with PNS manifestations and 14 (3.6%) with CNS manifestations. Prevalences were 9.2% for pure sensory neuropathy, 5.3% for sensorimotor neuropathy, 1.3% for cerebral vasculitis and 1.0% for myelitis. Neurological manifestations were associated with greater pSS activity as assessed using the ESSDAI (9.4+/-6.8 vs 4.3+/-4.8; p<0.001) and proportion of patients taking immunomodulatory/immunosuppressive drugs (32.4% (24/74) versus 13.8% (44/318), p=0003). New neurological symptoms were more common in patients with than without prior neurological manifestations (RR=3.918 (95% CI 1.91 to 8.05); p<0.001). CONCLUSIONS: Prevalences of peripheral and central neurological manifestations in pSS are about 15% and 5%, respectively. Neurological manifestations are associated with greater pSS activity. New neurological manifestations are more common in patients with prior neurological involvement.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Research team(s) :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Submission date :

2019-03-01T14:10:51Z
2022-07-06T09:56:58Z